On the kinetics and dynamics of tocainide and its metabolites

@article{Ronfeld1982OnTK,
  title={On the kinetics and dynamics of tocainide and its metabolites},
  author={Robert A. Ronfeld and E. M. Wolshin and Alan J. Block},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1982},
  volume={31}
}
The kinetics of tocainide, a new antiarrhythmic, and two of its metabolites, lactoxylidide (LX) and tocainide carbamoyl glucuronide (TG), were examined in patients given tocainide for 7 days following an acute myocardial infarction. In these patients kinetics were much the same as those reported for volunteers and for patients treated with tocainide for chronic extra ventricular beats. Mean half‐lifes for tocainide, LX, and TG were 13.6, 29.1, and 13 hr. At steady state mean metabolite to… Expand
Tocainide pharmacokinetics during continuous ambulatory peritoneal dialysis.
TLDR
This study examined selected tocainide pharmacokinetic variables in patients undergoing routine CAPD to examine the effect of continuous ambulatory peritoneal dialysis on the elimination of toCainide. Expand
Tocainide: A New Oral Antiarrhythmic
TLDR
Tocainide should be a useful agent in patients who are unable to tolerate other antiarrhythmics, who are responsive to lidocaine, or who have been troubled with Q-T prolongation with or without torsade de pointes. Expand
Stereoselective disposition of RS-tocainide in man
TLDR
Analysis of the disposition of RS-tocainide in three healthy volunteers after oral administration of a pseudoracemic mixture containing S( + ) [3H] tocainide as a radioactive tracer together with a therapeutic dose of the racemate indicated that the metabolite was preferably formed from the R(−) stereoisomer of toc Cainide. Expand
Tocainide: a new oral antiarrhythmic agent.
Tocainide, a newly released class 1B antiarrhythmic agent, has membrane stabilizing and electrophysiologic characteristics similar to those of lidocaine, but it can be prescribed for oralExpand
Tocainide kinetics in congestive heart failure
TLDR
There was a trend toward smaller volumes of distribution and higher average plasma concentrations at steady state in patients with congestive heart failure and the small number of patients suggests that further data collection is necessary before dosage recommendations can be made. Expand
Efficacy and toxicity of tocainide for the treatment of ventricular tachyarrhythmias in Doberman pinschers with occult cardiomyopathy.
TLDR
Tocainide led to a 70% reduction of the total numbers of ventricular premature contractions occurred in 80% of dogs treated, and ventricular tachycardia was eliminated in 90% of affected dogs by the time of the first posttreatment Holter recording. Expand
Pharmacokinetics of tocainide in patients with severe renal failure
TLDR
Creatinine clearance was shown to be a poor estimator of tocainide clearance, which suggests that extrarenal clearance plays an important role in the handling of the drug in the body. Expand
Analysis and stereoselective metabolism after separate oral doses of tocainide enantiomers to healthy volunteers.
TLDR
A method was developed to convert the N-carbamoylglucuronide of tocainide in plasma and urine by base treatment to a hydantoin derivative which after extraction and silation was analysed by selected ion monitoring using a deuterated internal standard to identify side-reactions during derivatization of the conjugate. Expand
Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
  • A. Pottage
  • Medicine
  • The American journal of cardiology
  • 1983
TLDR
New class I antiarrhythmic drugs differ in potency, adverse effects and pharmacokinetics, but their availability should increase the likelihood of success in the high-risk patient. Expand
Cardiac glycosides and drugs used in dysrhythmias
TLDR
The chapter suggests that preexisting evidence of interstitial lung abnormalities, particularly if associated with impaired diffusion capacity, should be a contraindication to the use of amiodarone. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 19 REFERENCES
Kinetics of the oral antiarrhythmie lidocaine congener, tocainide
TLDR
Tocainide, a primary amine analogue of lidocaine, is effective against some experimental and clinical arrhythmias and bioavailability approached 100%. Expand
Clinical Efficacy and Pharmacokinetics of a New Orally Effective Antiarrhythmic, Tocainide
TLDR
It is suggested that tocainide is a safe and effective antiarrhythmic agent during short-term administration and is worthy of further clinical trials. Expand
Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients.
TLDR
The antiarrhythmic efficacy and pharmacokinetics of tocainide, an oral analog of lidocaine, was evaluated in 18 hospitalized convalescing myocardial infarction patients and did not worsen chronic heart failure, even in patients with ejection fraction < 30%. Expand
Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias.
TLDR
It is concluded that tocainide is an effective oral agent for the therapy of potentially lethal ventricular arrhythmias refractory to other medication. Expand
Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide
TLDR
Glycinexylidide is a metabolite of lidocaine that is frequently present in µg/ml concentrations in the plasma of patients treated with lidocane infusions for 24 hr or more, and GX adversely affects the mental performance of normal subjects at plasma concentrations comparable to those found in patients. Expand
Antiarrhythmic potency of N‐acetylprocainamide
TLDR
Measurements of procainamide and NAPA plasma levels needed to suppress ventricular extrasystoles suggested that both compounds are nearly equipotent in patients as well, and dose regimens based onprocainamide levels alone need revision to include consideration of the levels of this metabolite. Expand
Tocainide conjugation in humans: novel biotransformation pathway for a primary amine.
TLDR
The metabolism of tocainide, an experimental antiarrhythmic drug, was studied in humans and a compound identified as 3-(2,6-xylyl)-5-methylhydantoin was derived from the same metabolite that formed the additional toc Cainide after acid or beta-glucuronidase treatment. Expand
Long-Term Tocainide Therapy for Ventricular Arrhythmias
TLDR
The data suggest that evaluation of longterm drug efficacy, using the criterion of reduction of asymptomatic arrhythmias, is best documented by multiple sequential ambulatory electrocardiographic recordings, both on and off the drug. Expand
Lorcainide; II. Plasma concentration‐effect relationship
TLDR
During the postinfusion period VPCs were remarkably more sensitive to plasma concentration than the changes in the ECG, and during the infusion period higher concentrations of lorcainide were required to induce antiarrhythmic and toxic effects than during the postInfusion period. Expand
Response optimization of drug dosage: Antiarrhythmie studies with tocainide
TLDR
Simulations were carried out to show the effect of various dosage regimens on antiarrhythmic response in individual patients, and demonstrate that for identical daily doses and dosing intervals patients show marked variability inAntiarrhythmmic response. Expand
...
1
2
...